Receptor tyrosine-protein kinase erbB-2–derived peptide–MHC complex (null)

Peptides derived from the receptor tyrosine-protein kinase erbB-2 (HER2) can be processed and presented on the cell surface in complex with major histocompatibility complex (MHC) class I or II molecules. These peptide–MHC complexes are recognized by T cells as part of the immune system’s surveillance for abnormal or cancer-associated proteins. HER2 is a member of the ErbB family of receptor tyrosine kinases and plays a pivotal role in cell proliferation and survival signaling. Overexpression or mutation of HER2 is associated with several cancers, notably breast and gastric cancer. HER2-derived peptide–MHC complexes are targets for peptide vaccines and adoptive cell therapies that aim to generate or enhance T cell–mediated antitumor immunity, though careful targeting is required to minimize damage to normal tissues expressing low levels of HER2 or presenting these peptides[1][3][4][6][7][8][10].

Other names

HER2 peptide–MHC complexERBB2-derived peptide–MHC complexHER2-derived peptide presented on MHC

Inhibition of HER2 signaling (block receptor activation/kinase activity by antibody or small-molecule inhibitor); Immune-mediated cytotoxicity (TCR-like or chimeric antigen receptor [CAR]-T cells recognize the HER2 peptide–MHC complex and kill the presenting cell)